Roche's Gazyva Breaks New Ground in Lupus
Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder of lupus, after clearing a phase 3 trial.
Gazyva, already approved for lupus nephritis, achieved its main objective in the ALLEGORY trial, increasing the proportion of patients showing improvement on the SLE Responder Index 4 (SRI-4) scale at 52 weeks, compared to placebo.
- Gazyva is an anti-CD20 antibody.
- Systemic lupus erythematosus (SLE) affects around 3.4 million people worldwide.
The results suggest that Gazyva could have broad utility in SLE and could become the first drug in the class for the disease.
Author's summary: Gazyva shows promise for lupus treatment.